Registered No. Intervention Patient Phase Start Year Sponsor Status
NCT01008358 CP 675,206 (tremelimumab) - Anti-CTLA antibody Unresectable HCC II 2008 Clinica Universidad de Navarra, Universidad de Navarra Completed
NCT00966251 Pidilizumab – anti-PD1 antibody Not operational HCC I/II 2009 CureTech Ltd. Terminated due to slow accrual
NCT01658878 Nivolumab – anti-PD1 antibody Advanced HCC I 2012 Bristol-Myers Squibb Recruiting
NCT01853618 Tremelimumab – anti-CTLA4 antibody Advanced HCC I 2013 National Cancer Institute (NCI) Recruiting
NCT02519348 MEDI4736 (anti-PD-L1 antibody), tremelimumab (anti-CTLA4 antibody) unresectable HCC I/II 2015 MedImmune LLC Not yet recruiting
Table 5: Clinical trials of checkpoints blockade on hepatocellular carcinoma.